Infliximab Side Effects in Refractory Takayasu Arteritis
Infliximab carries significant risks that require careful monitoring in your complex case, particularly serious infections (including tuberculosis and opportunistic infections), infusion reactions, hepatotoxicity, and potential malignancies—risks that are amplified by your concurrent immunosuppression with upadacitinib and mycophenolate, as well as your Dacron graft which increases infection susceptibility. 1
Most Common Side Effects
The most frequently reported adverse effects include 2:
- Upper respiratory tract infections (most common)
- Headache
- Increased hepatic enzymes (transaminitis)
- General infections
- Cough and stomach pain
Serious Infections (Critical in Your Case)
Your triple immunosuppression (infliximab + upadacitinib + mycophenolate) substantially elevates infection risk 1:
Specific Infection Risks:
- Tuberculosis reactivation – requires pre-treatment TB screening with chest imaging and testing
- Opportunistic infections: Pneumocystis pneumonia, histoplasmosis, coccidioidomycosis, aspergillosis, atypical mycobacteria
- Serious bacterial infections: pneumonia, septicemia, cellulitis, peritonitis
- Viral reactivation: hepatitis B (requires screening), herpes zoster
- Fungal infections: systemic candidiasis
In Takayasu arteritis cohorts treated with infliximab, serious infections occurred in approximately 20% of cases 3, 4. Your Dacron graft creates an additional nidus for infection, particularly with bacteremia.
Infusion-Related Reactions
Acute infusion reactions occur in 3-22% of patients 2:
- Fever, chills, chest pain
- Hypertension or hypotension
- Shortness of breath, rash, itching
- Rarely: anaphylactic shock requiring immediate intervention
Delayed hypersensitivity reactions (3-12 days post-infusion) 1:
- Fever, rash, headache, sore throat
- Muscle/joint pain, facial swelling, difficulty swallowing
Anti-infliximab antibodies develop in some patients, increasing immunological reaction risk and reducing efficacy 2.
Hepatotoxicity
Transaminase elevations are common but usually transient and asymptomatic 2. However:
- Rare cases of severe hepatitis and acute liver failure requiring transplantation or resulting in death have occurred
- Monitor liver enzymes regularly
- Watch for: jaundice, dark urine, right upper quadrant pain, severe fatigue 1
Cardiovascular Complications
Within 24 hours of infusion, patients have experienced 1:
- Myocardial infarction (some fatal)
- Low cardiac blood flow
- Arrhythmias
- Stroke
Symptoms requiring immediate evaluation: chest discomfort/pain, arm pain, shortness of breath, palpitations, sudden neurological changes.
Heart failure exacerbation can occur—particularly relevant given your aortic surgery history 1.
Hematologic Toxicity
Cytopenias (body fails to produce adequate blood cells) 1:
- Leukopenia, neutropenia (infection risk)
- Thrombocytopenia (bleeding risk)
- Anemia
Monitor for: persistent fever, easy bruising/bleeding, severe pallor.
Malignancy Risk
Increased cancer risk with TNF inhibitors 1:
- Skin cancers: Non-melanoma skin cancer (HR 1.7) and melanoma (HR 2.6) 2
- Lymphoma: Particularly hepatosplenic T-cell lymphoma (often fatal) in young males on combination therapy with azathioprine/6-mercaptopurine
- Regular dermatologic surveillance is mandatory
At 26 years old with long-term immunosuppression (7 years mycophenolate), your cumulative malignancy risk warrants heightened vigilance.
Neurological Complications
Rare but serious 1:
- Demyelinating disorders (multiple sclerosis-like syndrome)
- Guillain-Barré syndrome
- Seizures, optic neuritis
- Numbness, tingling, weakness
- Stroke (within 24 hours of infusion)
Autoimmune Phenomena
Lupus-like syndrome with positive autoantibodies 2:
- Chest pain, shortness of breath
- Joint pain, photosensitive rash
Paradoxical psoriasis (new onset or worsening) 1:
- Red scaly patches or pustular lesions
- May require infliximab discontinuation
Takayasu Arteritis-Specific Considerations
In refractory Takayasu arteritis cohorts 5, 3, 4, 6, 7:
- Infusion reactions: 2 cases reported in French cohort 3
- Serious infections: 1 pulmonary TB, 1 severe bacterial infection, 1 EBV reactivation in 15 patients 3
- Allergic reactions: Occurred in some patients requiring discontinuation 6
- Dose escalation (often needed in refractory cases like yours) may increase adverse event frequency 5
Critical Monitoring Requirements
Given your high-risk profile:
- Pre-treatment screening: TB testing (QuantiFERON/PPD + chest X-ray), hepatitis B/C serology
- Regular monitoring: CBC, liver enzymes, inflammatory markers (ESR/CRP)
- Infection surveillance: Low threshold for evaluation of fever, respiratory symptoms, or constitutional symptoms
- Vascular imaging: Annual surveillance for aneurysm/stenosis progression 8
- Dermatologic examination: Baseline and periodic skin cancer screening
- Graft surveillance: Given your Dacron graft, maintain heightened suspicion for graft infection
Drug Interactions
Your concurrent upadacitinib (JAK inhibitor) + mycophenolate creates additive immunosuppression 9. While this combination addresses refractory disease, it substantially amplifies infection risk beyond infliximab monotherapy. The evidence base for triple immunosuppression in Takayasu arteritis is limited to case reports.
Contraindications in Your Case
Avoid 1:
- Live vaccines (BCG, rotavirus, MMR, varicella) during and 6 months after therapy
- Concurrent use with other biologics (anakinra, abatacept, tocilizumab)
- Treatment during active infection
When to Stop Infliximab Immediately
Contact your physician urgently for 1:
- Signs of serious infection (fever, persistent cough, flu-like symptoms)
- Chest pain, shortness of breath, new cardiac symptoms
- Neurological changes (numbness, weakness, vision changes, seizures)
- Severe infusion reaction
- Jaundice or severe abdominal pain
- Easy bruising/bleeding or severe pallor
- New skin lesions concerning for malignancy
The decision to use infliximab in your case reflects the severity of refractory Takayasu arteritis, where benefits of disease control (preventing vascular complications, stroke, organ damage) outweigh substantial risks—but this requires meticulous monitoring and immediate response to warning signs.